{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:27:44Z","timestamp":1792661264208,"version":"4.5.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.addr.2021.114000","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T19:19:23Z","timestamp":1633979963000},"page":"114000","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":139,"special_numbering":"C","title":["Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic"],"prefix":"10.1016","volume":"179","author":[{"given":"Samagra","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijeet","family":"Venkataraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa E.","family":"Wechsler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Peppas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2021.114000_b0005","unstructured":"Bloomberg, \u201cBloomberg Vaccine Tracker,\u201d Bloomberg. https:\/\/www.bloomberg.com\/graphics\/covid-vaccine-tracker-global-distribution\/ (accessed May 19, 2021)."},{"key":"10.1016\/j.addr.2021.114000_b0010","doi-asserted-by":"crossref","unstructured":"S. Plotkin, \u201cHistory of vaccination,\u201d Proc. Natl. Acad. Sci., vol. 111, no. 34, Aug. 2014, doi: 10.1073\/pnas.1400472111.","DOI":"10.1073\/pnas.1400472111"},{"key":"10.1016\/j.addr.2021.114000_b0015","unstructured":"F. E. Andre, \u201cPolicy and practice Vaccination and reduction of disease and inequity,\u201d 2008."},{"issue":"1","key":"10.1016\/j.addr.2021.114000_b0020","doi-asserted-by":"crossref","first-page":"Dec","DOI":"10.1093\/bmb\/ldp028","article-title":"Global and regional causes of death","volume":"92","author":"Mathers","year":"2009","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.addr.2021.114000_b0025","doi-asserted-by":"crossref","unstructured":"A. Iwasaki and R. Medzhitov, \u201cRegulation of Adaptive Immunity by the Innate Immune System,\u201d Science (80-.)., vol. 327, no. 5963, Jan. 2010, doi: 10.1126\/science.1183021.","DOI":"10.1126\/science.1183021"},{"key":"10.1016\/j.addr.2021.114000_b0030","doi-asserted-by":"crossref","unstructured":"J. D. Joyce, A. K. Patel, B. Murphy, D. J. J. Carr, E. Gershburg, and A. S. Bertke, \u201cAssessment of Two Novel Live-Attenuated Vaccine Candidates for Herpes Simplex Virus 2 (HSV-2) in Guinea Pigs,\u201d Vaccines, vol. 9, no. 3, Mar. 2021, doi: 10.3390\/vaccines9030258.","DOI":"10.3390\/vaccines9030258"},{"key":"10.1016\/j.addr.2021.114000_b0035","doi-asserted-by":"crossref","unstructured":"J.-G. Park et al., \u201cArticle Immunogenicity and Protective Efficacy of an Intranasal Live-attenuated Vaccine Against SARS-CoV-2 in Preclinical Animal Models,\u201d Jan. 2021, doi: 10.1101\/2021.01.08.425974.","DOI":"10.1101\/2021.01.08.425974"},{"key":"10.1016\/j.addr.2021.114000_b0040","doi-asserted-by":"crossref","unstructured":"S. M. Bueno et al., \u201cInterim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial,\u201d 2021, doi: 10.1101\/2021.03.31.21254494.","DOI":"10.1101\/2021.03.31.21254494"},{"key":"10.1016\/j.addr.2021.114000_b0045","doi-asserted-by":"crossref","first-page":"Feb","DOI":"10.1016\/j.ejpb.2020.12.018","article-title":"Design of novel orotransmucosal vaccine-delivery platforms using artificial intelligence","volume":"159","author":"Garcia-del Rio","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2021.114000_b0050","doi-asserted-by":"crossref","DOI":"10.1002\/jbm.a.37203","article-title":"Modulation of injectable hydrogel properties for slow co-delivery of influenza subunit vaccine components enhance the potency of humoral immunity","author":"Saouaf","year":"2021","journal-title":"J. Biomed. Mater. Res. Part A"},{"issue":"1","key":"10.1016\/j.addr.2021.114000_b0055","doi-asserted-by":"crossref","first-page":"Dec","DOI":"10.3390\/vaccines9010001","article-title":"Advances in Oral Subunit Vaccine Design","volume":"9","author":"Van der Weken","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.addr.2021.114000_b0060","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiab185","article-title":"Limited flavivirus cross-reactive antibody responses elicited by a ZIKV DNA vaccine candidate in humans","author":"Burgomaster","year":"2021","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2021.114000_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100689","article-title":"Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial","volume":"31","author":"Tebas","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.addr.2021.114000_b0070","article-title":"Live attenuated vaccines: Historical successes and current challenges","volume":"479\u2013480","author":"Minor","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.addr.2021.114000_b0075","doi-asserted-by":"crossref","DOI":"10.3897\/rio.6.e53767","article-title":"An oral live attenuated vaccine strategy against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2\/2019-nCoV)","volume":"6","author":"Sanal","year":"2020","journal-title":"Res. Ideas Outcomes"},{"key":"10.1016\/j.addr.2021.114000_b0080","doi-asserted-by":"crossref","unstructured":"D. J. A. Crommelin, T. J. Anchordoquy, D. B. Volkin, W. Jiskoot, and E. Mastrobattista, \u201cAddressing the Cold Reality of mRNA Vaccine Stability,\u201d J. Pharm. Sci., vol. 110, no. 3, Mar. 2021, doi: 10.1016\/j.xphs.2020.12.006.","DOI":"10.1016\/j.xphs.2020.12.006"},{"issue":"3","key":"10.1016\/j.addr.2021.114000_b0085","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/infdis\/jix557","article-title":"Unraveling the Mucosal Immunity of Inactivated Poliovirus Vaccine","volume":"217","author":"Sutter","year":"2018","journal-title":"J. Infect. Dis."},{"issue":"18","key":"10.1016\/j.addr.2021.114000_b0090","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1510330","article-title":"Efficacy of a Single-Dose, Inactivated Oral Cholera Vaccine in Bangladesh","volume":"374","author":"Qadri","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.addr.2021.114000_b0095","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1177\/1535676020909998","article-title":"Comparing the Efficacy of Formaldehyde with Hydrogen Peroxide Fumigation on Infectious Bronchitis Virus","volume":"25","author":"Stuart","year":"2020","journal-title":"Appl. Biosaf."},{"issue":"5","key":"10.1016\/j.addr.2021.114000_b0100","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.0818-9641.2004.01272.x","article-title":"Vaccine adjuvants: Current state and future trends","volume":"82","author":"Petrovsky","year":"2004","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.addr.2021.114000_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(21)00020-7","article-title":"Inactivated COVID-19 vaccines to make a global impact","author":"Iversen","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.addr.2021.114000_b0110","article-title":"What\u2019s the Valneva COVID-19 vaccine, the French shot that\u2019s supposed to be \u2018variant proof\u2019?","author":"Taylor","year":"2021","journal-title":"The Conversation"},{"issue":"17\u201319","key":"10.1016\/j.addr.2021.114000_b0115","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1016\/S0264-410X(00)00519-3","article-title":"Tuberculosis subunit vaccine development: On the role of interferon-\u03b3","volume":"19","author":"Agger","year":"2001","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.addr.2021.114000_b0120","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nbt0398-292","article-title":"Efficacy of a food plant-based oral cholera toxin B subunit vaccine","volume":"16","author":"Arakawa","year":"1998","journal-title":"Nat. Biotechnol."},{"issue":"22","key":"10.1016\/j.addr.2021.114000_b0125","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults","volume":"372","author":"Lal","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"36","key":"10.1016\/j.addr.2021.114000_b0130","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1016\/j.vaccine.2020.06.062","article-title":"Immunogenicity generated by mRNA vaccine encoding VZV gE antigen is comparable to adjuvanted subunit vaccine and better than live attenuated vaccine in nonhuman primates","volume":"38","author":"Monslow","year":"2020","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.addr.2021.114000_b0135","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12250-020-00243-0","article-title":"mRNA Vaccines: Possible Tools to Combat SARS-CoV-2","volume":"35","author":"Yi","year":"2020","journal-title":"Virol. Sin."},{"key":"10.1016\/j.addr.2021.114000_b0140","doi-asserted-by":"crossref","unstructured":"J. W. Coffey, G. Das Gaiha, and G. Traverso, \u201cAnnual Review of Pharmacology and Toxicology Oral Biologic Delivery: Advances Toward Oral Subunit, DNA, and mRNA Vaccines and the Potential for Mass Vaccination During Pandemics,\u201d 2021, doi: 10.1146\/annurev-pharmtox-030320.","DOI":"10.1146\/annurev-pharmtox-030320-092348"},{"key":"10.1016\/j.addr.2021.114000_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2020.104236","article-title":"Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2","volume":"145","author":"Kalita","year":"2020","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.addr.2021.114000_b0150","doi-asserted-by":"crossref","unstructured":"G. Foglia, S. Shah, C. Luxemburger, and P. J. F. Pietrobon, \u201cClostridium difficile: Development of a novel candidate vaccine,\u201d Vaccine, vol. 30, no. 29, Jun. 2012, doi: 10.1016\/j.vaccine.2012.01.056.","DOI":"10.1016\/j.vaccine.2012.01.056"},{"key":"10.1016\/j.addr.2021.114000_b0155","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0065-2660(05)54011-2","article-title":"DNA Vaccine","volume":"54","author":"Cui","year":"2005","journal-title":"Advances in Genetics"},{"key":"10.1016\/j.addr.2021.114000_b0160","doi-asserted-by":"crossref","unstructured":"M. D. Knoll and C. Wonodi, \u201cOxford\u2013AstraZeneca COVID-19 vaccine efficacy,\u201d Lancet, vol. 397, no. 10269, Jan. 2021, doi: 10.1016\/S0140-6736(20)32623-4.","DOI":"10.1016\/S0140-6736(20)32623-4"},{"key":"10.1016\/j.addr.2021.114000_b0165","article-title":"Covid-19: US suspends Johnson and Johnson vaccine rollout over blood clots","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.addr.2021.114000_b0170","unstructured":"WHO, \u201cWHO Coronavirus (COVID-19) Dashboard,\u201d 2021. Accessed: May 19, 2021. [Online]. Available: https:\/\/covid19.who.int\/."},{"issue":"2","key":"10.1016\/j.addr.2021.114000_b0175","doi-asserted-by":"crossref","first-page":"Aug","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.addr.2021.114000_b0180","doi-asserted-by":"crossref","first-page":"Sep","DOI":"10.1038\/sj.cgt.7701072","article-title":"mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes","volume":"14","author":"Mockey","year":"2007","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.addr.2021.114000_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2016.09.006","article-title":"Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles in vivo","volume":"109","author":"Kauffman","year":"2016","journal-title":"Biomaterials"},{"issue":"4","key":"10.1016\/j.addr.2021.114000_b0190","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines-a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2021.114000_b0195","doi-asserted-by":"crossref","unstructured":"R. J. Y. Ho, \u201cWarp-Speed Covid-19 Vaccine Development: Beneficiaries of Maturation in Biopharmaceutical Technologies and Public-Private Partnerships,\u201d J. Pharm. Sci., vol. 110, no. 2, Feb. 2021, doi: 10.1016\/j.xphs.2020.11.010.","DOI":"10.1016\/j.xphs.2020.11.010"},{"key":"10.1016\/j.addr.2021.114000_b0200","article-title":"Covid-19: Pfizer-BioNTech vaccine is rolled out in US","author":"Tanne","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.addr.2021.114000_b0205","doi-asserted-by":"crossref","unstructured":"E. Dolgin, \u201cHow COVID unlocked the power of RNA vaccines,\u201d Nature, Jan. 12, 2021.","DOI":"10.1038\/d41586-021-00019-w"},{"issue":"10","key":"10.1016\/j.addr.2021.114000_b0210","doi-asserted-by":"crossref","first-page":"Oct","DOI":"10.1021\/acsnano.0c07197","article-title":"COVID-19 Vaccine Frontrunners and Their Nanotechnology Design","volume":"14","author":"Chung","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2021.114000_b0215","unstructured":"Novavax, \u201cA Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults \u2265 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) at Risk for SARS-CoV-2,\u201d Clin. Trial, 2021."},{"key":"10.1016\/j.addr.2021.114000_b0220","unstructured":"CDC, \u201cWhen You\u2019ve Been Fully Vaccinated,\u201d May 2021. Accessed: May 20, 2021. [Online]. Available: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/fully-vaccinated.html."},{"key":"10.1016\/j.addr.2021.114000_b0225","unstructured":"CDC, \u201cDelta Variant: What We Know About the Science,\u201d Aug. 2021."},{"key":"10.1016\/j.addr.2021.114000_b0230","unstructured":"CDC, \u201cTalking with Patients Who Are Immunocompromised,\u201d Aug. 2021."},{"key":"10.1016\/j.addr.2021.114000_b0235","doi-asserted-by":"crossref","unstructured":"E. J. Haas et al., \u201cImpact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data,\u201d Lancet, vol. 397, no. 10287, May 2021, doi: 10.1016\/S0140-6736(21)00947-8.","DOI":"10.1016\/S0140-6736(21)00947-8"},{"key":"10.1016\/j.addr.2021.114000_b0240","unstructured":"R. Tenchov, \u201cUnderstanding the nanotechnology in COVID-19 vaccines,\u201d CAS, Feb. 2021. https:\/\/www.cas.org\/resource\/blog\/understanding-nanotechnology-covid-19-vaccines (accessed May 20, 2021)."},{"key":"10.1016\/j.addr.2021.114000_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2021.03.043","article-title":"The dawn of mRNA vaccines: The COVID-19 case","volume":"333","author":"Verbeke","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.114000_b0250","doi-asserted-by":"crossref","unstructured":"F. Kowalzik, D. Schreiner, C. Jensen, D. Teschner, S. Gehring, and F. Zepp, \u201cmRNA-Based Vaccines,\u201d Vaccines, vol. 9, no. 4, Apr. 2021, doi: 10.3390\/vaccines9040390.","DOI":"10.3390\/vaccines9040390"},{"key":"10.1016\/j.addr.2021.114000_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2016.05.008","article-title":"Recent innovations in mRNA vaccines","volume":"41","author":"Ulmer","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.addr.2021.114000_b0260","doi-asserted-by":"crossref","unstructured":"A. K. Blakney, S. Ip, and A. J. Geall, \u201cAn Update on Self-Amplifying mRNA Vaccine Development,\u201d Vaccines, vol. 9, no. 2, Jan. 2021, doi: 10.3390\/vaccines9020097.","DOI":"10.3390\/vaccines9020097"},{"key":"10.1016\/j.addr.2021.114000_b0265","doi-asserted-by":"crossref","unstructured":"B. Leyman et al., \u201cComparison of the Expression Kinetics and Immunostimulatory Activity of Replicating mRNA, Nonreplicating mRNA, and pDNA after Intradermal Electroporation in Pigs,\u201d Mol. Pharm., vol. 15, no. 2, Feb. 2018, doi: 10.1021\/acs.molpharmaceut.7b00722.","DOI":"10.1021\/acs.molpharmaceut.7b00722"},{"key":"10.1016\/j.addr.2021.114000_b0270","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.608460","article-title":"RNA Vaccines: A Suitable Platform for Tackling Emerging Pandemics?","volume":"11","author":"Sandbrink","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2021.114000_b0275","article-title":"Advances in mRNA Vaccines for Infectious Diseases","volume":"10","author":"Zhang","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2021.114000_b0280","doi-asserted-by":"crossref","unstructured":"E. Bettini and M. Locci, \u201cSARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond,\u201d Vaccines, vol. 9, no. 2, Feb. 2021, doi: 10.3390\/vaccines9020147.","DOI":"10.3390\/vaccines9020147"},{"key":"10.1016\/j.addr.2021.114000_b0285","doi-asserted-by":"crossref","unstructured":"A. Ghaffari, R. Meurant, and A. Ardakani, \u201cCOVID-19 Serological Tests: How Well Do They Actually Perform?,\u201d Diagnostics 2020, Vol. 10, Page 453, vol. 10, no. 7, p. 453, Jul. 2020, doi: 10.3390\/DIAGNOSTICS10070453.","DOI":"10.3390\/diagnostics10070453"},{"issue":"1","key":"10.1016\/j.addr.2021.114000_b0290","doi-asserted-by":"crossref","first-page":"Dec","DOI":"10.1038\/s41541-020-0159-8","article-title":"The promise of mRNA vaccines: a biotech and industrial perspective","volume":"5","author":"Jackson","year":"2020","journal-title":"npj Vaccines"},{"key":"10.1016\/j.addr.2021.114000_b0295","unstructured":"Mark Terry, \u201cUPDATED Comparing COVID-19 Vaccines: Timelines, Types and Prices,\u201d BioSpace, 2021. https:\/\/www.biospace.com\/article\/comparing-covid-19-vaccines-pfizer-biontech-moderna-astrazeneca-oxford-j-and-j-russia-s-sputnik-v\/ (accessed May 20, 2021)."},{"key":"10.1016\/j.addr.2021.114000_b0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2020.05.091","article-title":"Effect of a wet market on coronavirus disease (COVID-19) transmission dynamics in China, 2019\u20132020","volume":"97","author":"Mizumoto","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.addr.2021.114000_b0305","doi-asserted-by":"crossref","unstructured":"S. F. Pedersen and Y.-C. Ho, \u201cSARS-CoV-2: a storm is raging,\u201d J. Clin. Invest., vol. 130, no. 5, Apr. 2020, doi: 10.1172\/JCI137647.","DOI":"10.1172\/JCI137647"},{"key":"10.1016\/j.addr.2021.114000_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108448","article-title":"COVID-19: Immunology and treatment options","volume":"215","author":"Felsenstein","year":"2020","journal-title":"Clin. Immunol."},{"issue":"1","key":"10.1016\/j.addr.2021.114000_b0315","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/JVI.01786-15","article-title":"Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin","volume":"90","author":"Brazzoli","year":"2016","journal-title":"J. Virol."},{"issue":"12","key":"10.1016\/j.addr.2021.114000_b0320","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/nbt.2436","article-title":"Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection","volume":"30","author":"Petsch","year":"2012","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"10.1016\/j.addr.2021.114000_b0325","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","article-title":"Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses","volume":"25","author":"Bahl","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2021.114000_b0330","doi-asserted-by":"crossref","unstructured":"A. Pattnaik, B. R. Sahoo, and A. K. Pattnaik, \u201cCurrent Status of Zika Virus Vaccines: Successes and Challenges,\u201d Vaccines, vol. 8, no. 2, May 2020, doi: 10.3390\/vaccines8020266.","DOI":"10.3390\/vaccines8020266"},{"issue":"6","key":"10.1016\/j.addr.2021.114000_b0335","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified mRNA Vaccines Protect against Zika Virus Infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.addr.2021.114000_b0340","doi-asserted-by":"crossref","unstructured":"Z. Mu, B. F. Haynes, and D. W. Cain, \u201cHIV mRNA Vaccines\u2014Progress and Future Paths,\u201d Vaccines, vol. 9, no. 2, Feb. 2021, doi: 10.3390\/vaccines9020134.","DOI":"10.3390\/vaccines9020134"},{"issue":"17","key":"10.1016\/j.addr.2021.114000_b0345","doi-asserted-by":"crossref","first-page":"Nov","DOI":"10.1097\/QAD.0000000000002026","article-title":"Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection","volume":"32","author":"Leal","year":"2018","journal-title":"AIDS"},{"issue":"12","key":"10.1016\/j.addr.2021.114000_b0350","first-page":"Oct","article-title":"Correction: Preclinical evaluation of an mRNA HIV vaccine combining rationally selected antigenic sequences and adjuvant signals (HTI-TriMix)","volume":"33","author":"Leal","year":"2019","journal-title":"AIDS"},{"key":"10.1016\/j.addr.2021.114000_b0355","doi-asserted-by":"crossref","unstructured":"P. Venkatesan, \u201cPreliminary phase 1 results from an HIV vaccine candidate trial,\u201d The Lancet Microbe, vol. 2, no. 3, Mar. 2021, doi: 10.1016\/S2666-5247(21)00042-2.","DOI":"10.1016\/S2666-5247(21)00042-2"},{"issue":"4","key":"10.1016\/j.addr.2021.114000_b0360","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1128\/CMR.00035-09","article-title":"Dengue virus pathogenesis: An integrated view","volume":"22","author":"Martina","year":"2009","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.addr.2021.114000_b0365","doi-asserted-by":"crossref","unstructured":"D. J. Gubler, \u201cDengue and dengue hemorrhagic fever,\u201d Clinical Microbiology Reviews, vol. 11, no. 3. American Society for Microbiology, pp. 480\u2013496, Jul. 01, 1998, doi: 10.1128\/cmr.11.3.480.","DOI":"10.1128\/CMR.11.3.480"},{"key":"10.1016\/j.addr.2021.114000_b0370","first-page":"1","article-title":"A modified mRNA vaccine targeting immunodominant NS epitopes protects against dengue virus infection in HLA class I transgenic mice","volume":"vol. 10, no. JUN","author":"Roth","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2021.114000_b0375","unstructured":"\u201cRabies,\u201d WHO, 2021. ."},{"issue":"6","key":"10.1016\/j.addr.2021.114000_b0380","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0004746","article-title":"An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs","volume":"10","author":"Schnee","year":"2016","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"10101","key":"10.1016\/j.addr.2021.114000_b0385","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","article-title":"Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2021.114000_b0390","doi-asserted-by":"crossref","unstructured":"A. W. Freyn et al., \u201cA Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice,\u201d Mol. Ther., vol. 28, no. 7, Jul. 2020, doi: 10.1016\/j.ymthe.2020.04.018.","DOI":"10.1016\/j.ymthe.2020.04.018"},{"key":"10.1016\/j.addr.2021.114000_b0395","doi-asserted-by":"crossref","unstructured":"R. Nachbagauer et al., \u201cA chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial,\u201d Nat. Med., vol. 27, no. 1, Jan. 2021, doi: 10.1038\/s41591-020-1118-7.","DOI":"10.1038\/s41591-020-1118-7"},{"key":"10.1016\/j.addr.2021.114000_b0400","doi-asserted-by":"crossref","unstructured":"Nature Nanotechnology, \u201cNanomedicine and the COVID-19 vaccines,\u201d Nat. Nanotechnol., vol. 15, no. 12, Dec. 2020, doi: 10.1038\/s41565-020-00820-0.","DOI":"10.1038\/s41565-020-00820-0"},{"key":"10.1016\/j.addr.2021.114000_b0405","doi-asserted-by":"crossref","unstructured":"P. Sellaturay, S. Nasser, S. Islam, P. Gurugama, and P. W. Ewan, \u201cPolyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer\/BioNTech mRNA COVID\u201019 vaccine,\u201d Clin. Exp. Allergy, vol. 51, no. 6, Jun. 2021, doi: 10.1111\/cea.13874.","DOI":"10.1111\/cea.13874"},{"key":"10.1016\/j.addr.2021.114000_b0410","doi-asserted-by":"crossref","unstructured":"T. T. Hoang Thi, E. H. Pilkington, D. H. Nguyen, J. S. Lee, K. D. Park, and N. P. Truong, \u201cThe Importance of Poly(ethylene glycol) Alternatives for Overcoming PEG Immunogenicity in Drug Delivery and Bioconjugation,\u201d Polymers (Basel)., vol. 12, no. 2, Feb. 2020, doi: 10.3390\/polym12020298.","DOI":"10.3390\/polym12020298"},{"key":"10.1016\/j.addr.2021.114000_b0415","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/680620","article-title":"Towards Targeted Delivery Systems: Ligand Conjugation Strategies for mRNA Nanoparticle Tumor Vaccines","volume":"2015","author":"Phua","year":"2015","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.addr.2021.114000_b0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2020.111378","article-title":"Mannose-functionalized antigen nanoparticles for targeted dendritic cells, accelerated endosomal escape and enhanced MHC-I antigen presentation","volume":"197","author":"Pei","year":"2021","journal-title":"Colloids Surfaces B Biointerfaces"},{"key":"10.1016\/j.addr.2021.114000_b0425","doi-asserted-by":"crossref","DOI":"10.1111\/j.1469-0691.2012.03981.x","article-title":"Rotavirus vaccination: a concise review","volume":"18","author":"Vesikari","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.addr.2021.114000_b0430","doi-asserted-by":"crossref","first-page":"May","DOI":"10.1016\/j.addr.2017.04.008","article-title":"Current state and challenges in developing oral vaccines","volume":"114","author":"Vela Ramirez","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2021.114000_b0435","doi-asserted-by":"crossref","unstructured":"M. Dur\u00e1n-Lobato, B. Carrillo-Conde, Y. Khairandish, and N. A. Peppas, \u201cSurface-Modified P(HEMA- co -MAA) Nanogel Carriers for Oral Vaccine Delivery: Design, Characterization, and In Vitro Targeting Evaluation,\u201d Biomacromolecules, vol. 15, no. 7, Jul. 2014, doi: 10.1021\/bm500588x.","DOI":"10.1021\/bm500588x"},{"key":"10.1016\/j.addr.2021.114000_b0440","doi-asserted-by":"crossref","unstructured":"M. Skwarczynski and I. Toth, \u201cNon-invasive mucosal vaccine delivery: advantages, challenges and the future,\u201d Expert Opin. Drug Deliv., vol. 17, no. 4, Apr. 2020, doi: 10.1080\/17425247.2020.1731468.","DOI":"10.1080\/17425247.2020.1731468"},{"issue":"33","key":"10.1016\/j.addr.2021.114000_b0445","doi-asserted-by":"crossref","first-page":"Aug","DOI":"10.1016\/j.vaccine.2018.05.087","article-title":"Chitosan\/alginate microparticles for the oral delivery of fowl typhoid vaccine: Innate and acquired immunity","volume":"36","author":"Onuigbo","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.114000_b0450","doi-asserted-by":"crossref","unstructured":"K.-C. Kwon, D. Verma, N. D. Singh, R. Herzog, and H. Daniell, \u201cOral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells,\u201d Adv. Drug Deliv. Rev., vol. 65, no. 6, Jun. 2013, doi: 10.1016\/j.addr.2012.10.005.","DOI":"10.1016\/j.addr.2012.10.005"},{"issue":"1","key":"10.1016\/j.addr.2021.114000_b0455","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-pharmtox-030320-092348","article-title":"Oral biologic delivery: advances toward oral subunit, DNA, and MRNA vaccines and the potential for mass vaccination during pandemics","volume":"61","author":"Coffey","year":"2021","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.addr.2021.114000_b0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2015.09.069","article-title":"Shape and size-dependent immune response to antigen-carrying nanoparticles","volume":"220","author":"Kumar","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.114000_b0465","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201801180","article-title":"Microneedle-Mediated Vaccine Delivery to the Oral Mucosa","author":"Creighton","year":"2018","journal-title":"Adv. Healthc. Mater."},{"issue":"1","key":"10.1016\/j.addr.2021.114000_b0470","doi-asserted-by":"crossref","first-page":"Dec","DOI":"10.1038\/s41467-019-08739-4","article-title":"HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge","volume":"10","author":"Jones","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2021.114000_b0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2016.07.036","article-title":"Multi-layered nanofibrous mucoadhesive films for buccal and sublingual administration of drug-delivery and vaccination nanoparticles - important step towards effective mucosal vaccines","volume":"249","author":"Ma\u0161ek","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.114000_b0480","unstructured":"World Bank, \u201c\u2018Absolutely Unacceptable\u2019 COVID-19 Vaccination Rates in Developing Countries | The Development Podcast,\u201d World Bank Podcast, Aug. 03, 2021. ."},{"issue":"1","key":"10.1016\/j.addr.2021.114000_b0485","doi-asserted-by":"crossref","first-page":"Dec","DOI":"10.1038\/s41467-018-05041-7","article-title":"Neutralization of the Plasmodium-encoded MIF ortholog confers protective immunity against malaria infection","volume":"9","author":"Baeza Garcia","year":"2018","journal-title":"Nat. Commun."}],"updated-by":[{"DOI":"10.1016\/j.addr.2022.114501","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000}}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X21003938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X21003938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T14:00:58Z","timestamp":1673445658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X21003938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":97,"alternative-id":["S0169409X21003938"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2021.114000","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.addr.2022.114501","asserted-by":"object"}]},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2021.114000","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114000"}}